US Pat. No. 10,136,813

SYSTEMS AND METHODS FOR PATIENT CARDIOVASCULAR AND RESPIRATORY MANAGEMENT

1. A method for displaying integrated graphics for diagnostics for a patient's physiology, the method comprising:displaying a cardiac graphic object representing cardiac performance based on at least one measurement from the patient's left ventricle performance, said cardiac graphic object including at least a first, second, and third physiological parameter;
displaying at least one dynamic graphical line from the first physiological parameter being displayed to the second physiological parameter being displayed, and wherein the displaying of the dynamic graphical line comprises illustrating at least one functional relationship between the first and second physiological parameters;
displaying a pulmonary graphic object representing pulmonary performance, wherein displaying the pulmonary graphic object comprises displaying pulmonary vascular blood flow, and wherein the displaying the pulmonary vascular blood flow comprises displaying at least one measurement based on the patient's pulmonary arterial blood pressure and at least one measurement based on the patient's pulmonary venous blood pressure, and at least one measurement based on the patient's pulmonary vascular resistance; and
displaying a systemic vascular graphic object representing systemic cardiovascular performance, wherein displaying the systemic vascular graphic object comprises displaying systemic vascular blood flow, wherein the displaying the systemic vascular blood flow comprises displaying at least one measurement based on the patient's systemic arterial blood pressure and at least one measurement based on the patient's systemic venous blood pressure, and at least one measurement based on the patient's systemic vascular resistance.

US Pat. No. 10,136,806

IMAGE DISPLAY METHOD, IMAGE DISPLAY APPARATUS, AND STORAGE MEDIUM

Canon Kabushiki Kaisha, ...

1. An image display method comprising:acquiring a first image of a fundus within a first area of an eye to be inspected;
acquiring interference signal sets corresponding to a plurality of frames, which are acquired with an intention to acquire the same cross section, for a plurality of different cross sections;
generating, based on the interference signal sets corresponding to the plurality of frames, a motion contrast image of the fundus within a second area included in the first area; and
superimposing, for display, information acquired from a portion of the motion contrast image of the fundus onto a corresponding position of the first image of the fundus.

US Pat. No. 10,136,802

DEVICE FOR SUSTAINED RELEASE OF OPTICAL CLEARING AGENT, ENDOSCOPE HAVING THE SAME, AND INSTRUMENT FOR ENDOSCOPIC SURGERY HAVING THE SAME

OLYMPUS CORPORATION, Tok...

1. A method for achieving sustained release of optical clearing agent comprising:(a) inserting into a lumen a device for sustained release of optical clearing agent without inflating any of at least two pouch-shaped elastic components of the device, the device comprising:
a stick-shaped component inside which at least two supplying passages are formed for supplying gas or liquid and which has apertures of the respective supplying passages formed at positions in a vicinity of a top end of the stick-shaped component along a circumference of a lateral surface thereof,
the at least two pouch-shaped elastic components placed at positions in the vicinity of the top end of the stick-shaped component along the circumference of the lateral surface of the stick-shaped component to cover the respective apertures of the supplying passages respectively;
(b) moving the device for sustained release of optical clearing agent so that the top end of the stick-shaped component, where the pouch-shaped elastic components are provided, is positioned to a diseased region on a wall surface of the lumen;
(c) rotating the stick-shaped component via a rotary unit until a body-fluid absorbing component fixed on a surface of a first pouch-shaped elastic component, which is one of the at least two pouch-shaped elastic components, is made to face the diseased region;
(d) infusing gas or liquid into the first pouch-shaped elastic component from the aperture of a first supplying passage, which is one of the at least two supplying passages inside the stick-shaped component, via the first supplying passage, to inflate the first pouch-shaped elastic component;
(e) pressing the body-fluid absorbing component against the diseased region through deformation of the first pouch-shaped elastic component, to make the body-fluid absorbing component absorb body fluid on a surface of and from inside the diseased region;
(f) discharging the gas or fluid from inside the first pouch-shaped elastic component through the aperture of the first supplying passage, to deflate the first pouch-shaped elastic component and detach the body-fluid absorbing component from the diseased region;
(g) rotating the stick-shaped component via the rotary unit until an optical clearing agent holding component fixed on a surface of a second pouch-shaped elastic component, which is one of the at least two pouch-shaped elastic components, is made to face the diseased region;
(h) infusing gas or liquid into the second pouch-shaped elastic component from the aperture of a second supplying passage, which is one of the at least two supplying passages inside the stick-shaped component, via the second supplying passage, to inflate the second pouch-shaped elastic component; and
(i) pressing the optical clearing agent holding component against the diseased region through deformation of the second pouch-shaped elastic component, to establish sustained release of optical clearing agent held by the optical clearing agent holding component to the diseased region.

US Pat. No. 10,136,801

BENDING PORTION AND ENDOSCOPE

OLYMPUS CORPORATION, Tok...

1. A bending portion in which a plurality of bending pieces are pivotably continuously provided, the bending portion comprising:a first bending piece and a second bending piece provided adjacent to each other;
the first bending piece comprising:
a circular convex portion comprising a peripheral portion having a circular arc shape;
a support portion extended along an axial line direction of the first bending piece from a circular convex portion and supporting the circular convex portion;
a pair of engaging concave portions provided so as to sandwich the circular convex portion and the support portion; and
a pair of distal-end-side contact portions respectively extended from the engaging concave portions in an opposite direction of the circular convex portion,
the pair of engaging concave portions each comprising:
a first inclined portion extended from the support portion in a direction to form an obtuse angle with the support portion;
a second inclined portion extended from the first inclined portion in a direction to form an obtuse angle with the first inclined portion; and
an inside portion that is bent in an obtuse angle with respect to the second inclined portion and extended along a concentric arc of the peripheral portion so as to be adjacent to the distal-end-side contact portion; and
the second bending piece comprising:
a circular concave portion comprising an inside portion having a circular arc shape configured to slide with respect to the peripheral portion, the circular concave portion being provided so as to be pivotable around the circular convex portion;
a pair of engaging convex portions provided so as to sandwich the circular concave portion; and
a pair of proximal-end-side contact portions respectively extended from the engaging convex portions in an opposite direction from the circular concave portion, the pair of proximal-end-side contact portions being configured to come into contact with the distal-end-side contact portions when the circular concave portion pivots around the circular convex portion,
the pair of engaging convex portions each comprising:
 a pair of pointed portions having a shape along the support portion, the first inclined portion, and the second inclined portion, one of the pair of pointed portions being placed at a back of the engaging concave portion to face the support portion, the first inclined portion, and the second inclined portion when the distal-end-side contact portions and the proximal-end-side contact portion contact with each other; and
 an outside portion that is bent in an obtuse angle with respect to the pointed portions and extended along a concentric arc of the inside portion so as to be adjacent to the proximal-end-side contact portion.

US Pat. No. 10,136,797

ENDOSCOPE WITH EXTERNAL DEVICE CONNECTOR

FUJIFILM Corporation, To...

1. An endoscope apparatus, comprisingan insertion part that is inserted into a body cavity of a subject;
an operating part that is connected to the insertion part;
a universal cord that extends from the operating part; and
a connector part that is provided at a terminal of the universal cord away from the insertion part and is connected to an external device and transmits and receives a light signal to and from the external device,
wherein the connector part comprises:
a hollow metal member having two openings that communicate with each other;
an optical semiconductor element that is fixed to one opening side of the hollow metal member so as to be capable of sealing the periphery of the one opening;
a lens that is provided on the other opening side of the hollow metal member; and
a first sealing member that fixes the lens to the hollow metal member and seals a gap between the lens and the hollow metal member.

US Pat. No. 10,136,795

DISH RACK RETAINING CLIP

Whirlpool Corporation, B...

1. A dish rack assembly, comprising:a dish rack having spaced wire frame elements at least partially defining a dish rack side wall and configured to retain dishes;
a height adjuster comprising an arm located on an exterior of the dish rack side wall having a pair of spaced first ribs extending therefrom with each of the pair of spaced first ribs extending along a different wire frame element, the height adjust further including a lever and wherein the arm is configured to be operably coupled to a tub side wall and the lever is configured to move the arm vertically to adjust the height of the dish rack with respect to the tub side wall; and
a retaining clip located on an interior of the dish rack side wall and having a planar body with a pair of second ribs extending therefrom, each of the pair of second ribs is complementary to each of the pair of first ribs;
wherein the retaining clip is mounted to the arm such that a first of the pair of first ribs and a first of the pair of second ribs are directly adjacent opposite lateral sides of a first of the spaced wire frame elements and the arm and retaining clip are on opposite sides, transverse to the lateral sides, of the first of the spaced wire frame elements and a second of the pair of first ribs and a second of the pair of second ribs are directly adjacent opposite lateral sides of a second of the spaced wire frame elements and the arm and retaining clip are on opposite sides, transverse to the lateral sides, of the second of the spaced wire frame elements.
US Pat. No. 10,138,490

TRANSFORMED PLANTS TOLERANT TO HERBICIDES DUE TO OVEREXPRESSION OF PREPHENATE DEHYDROGENASE AND P-HYDROXYPHENYLPYRUVATE DIOXYGENASE

1. A method for cultivating a transformed plant, the method comprisinga) planting a seed of the transformed plant,
b) contacting the seed or a transformed plant grown from the seed with a herbicidal composition comprising an inhibitor of p-hydroxyphenylpyruvate dioxygenase, and
c) cultivating the plant, wherein the transformed seed or the transformed plant is substantially unaffected by the herbicidal composition, wherein the plant comprises:
(1) a first gene that is functional in a plant, wherein the first gene comprises a nucleotide sequence that encodes a yeast prephenate dehydrogenase, and
(2) a second gene that is functional in a plant, wherein the second gene comprises a nucleotide sequence that encodes a p-hydroxyphenylpyruvate dioxygenase, and
wherein the plant overexpresses the prephenate dehydrogenase and the p-hydroxyphenylpyruvate dioxygenase, and wherein said plant is tolerant to an amount of said inhibitor that is toxic to or decreases the growth of plants transformed with said second gene alone.
US Pat. No. 10,137,215

ORGANIC WASTE ODOR ABSORBER

1. A method of treating organic waste comprising:a step of placing a composition within a receptacle to create a layer on the bottom of said receptacle;
a step of placing organic waste within said receptacle already containing the layer of said composition, where said organic waste is placed on top of said composition;
a step of placing additional said composition on top of said organic waste within said receptacle;wherein said composition's materials comprise:a. 35% to 85% holocellulose, by weight
b. 8% to 30% lignin, by weight
c. 40% to 80% silica, by weight;wherein said composition comprises dried materials;wherein said composition's materials comprise a particle size range from 0.002 millimeters in diameter to 300 by 300 by 300 millimeters;wherein said composition comprises a scent;wherein said organic waste is composted.
US Pat. No. 10,138,500

D-LACTIC ACID-PRODUCING STRAIN AND USE THEREOF

CJ CHEIJEDANG CORPORATION...

1. A D-lactic acid-producing strain modified to attenuate or inactivate L-lactate dehydrogenase (L-LDH) activity and to enhance D-lactate dehydrogenase (D-LDH) activity, wherein the D-lactic acid-producing strain so modified is a Lactobacillus sp strain which produces more L-lactic acid than D-lactic acid prior to said modification; wherein the L-LDH activity is derived from a L-LDH-encoding polynucleotide from Lactobacillus paracasei, Lactobacillus casei, or Lactobacillus rhamnosus; wherein the D-LDH activity is derived from a D-LDH-encoding polynucleotide from Lactobacillus plantarum or Lactobacillus delbrueckii; and wherein the Lactobacillus sp. strain is selected from the group consisting of Lactobacillus casei, Lactobacillus paracasei, and Lactobacillus rhamnosus.
US Pat. No. 10,136,708

LIGHT PRECIOUS ALLOY OF GOLD AND TITANIUM AND COMPONENTS FOR TIMEPIECES OR JEWELLERY MADE FROM SUCH A LIGHT PRECIOUS ALLOY OF GOLD AND TITANIUM

1. A light, precious gold-titanium based alloy comprising, by mass, from 750‰ to 780‰ of gold,wherein said alloy has the following composition formula:
TiaAubMcTd
where a b, c, d are atomic proportions such that:
a+b+c+d=1,
0.45?a?0.55; 0.41?b?0.495; 0.025?c?0.13; 0.001?d?0.025,
wherein M represents at least one element selected from the group consisting of Nb, V, Pd, Pt, and Fe, and
T represents boron and optionally an additional element, and
wherein the additional element is selected from the group consisting of Nb, V, Pd, Pt, Fe, Mo, Ta, W, Co, Ni, Ru, Rh, Ir, Cr, Mn, Cu, Zn, Ag, Al, Si, Ge, Sn, Sb, and In,
M and T are different elements, and
the alloy comprises the boron as T or as a part of T in an atomic content of from 0.03% to 0.3%.
US Pat. No. 10,137,733

PNEUMATIC TIRE

SUMITOMO RUBBER INDUSTRIE...

1. A pneumatic tire, comprising a tread formed from a rubber composition,the rubber composition comprising:
an oil-extended polybutadiene rubber having a cis content of 95 mol % or more, a vinyl content of 1 mol % or less, and a weight average molecular weight of 530,000 or more;
at least one of an isoprene-based diene rubber or a styrene-butadiene rubber;
a carbon black having a nitrogen adsorption specific surface area of 110 to 200 m2/g; and
stearic acid,
the oil-extended polybutadiene rubber being synthesized using a rare earth catalyst,
the rubber composition comprising, based on 100% by mass of the total rubber solids, 8% to 65% by mass of a polybutadiene rubber component contained in the oil-extended polybutadiene rubber and 20% to 85% by mass of the at least one of an isoprene-based diene rubber or a styrene-butadiene rubber,
the rubber composition comprising, relative to 100 parts by mass of the total rubber solids, 20 to 100 parts by mass of the carbon black and 1.5 to 2.99 parts by mass of the stearic acid,
the rubber composition having an amount of process oil of 9 parts by mass or less relative to 100 parts by mass of the total rubber solids.
US Pat. No. 10,137,222

FIBRIN COMPOSITION, METHOD AND WOUND ARTICLES

3M INNOVATIVE PROPERTIES ...

1. A method of forming a fibrin hydrogel composition comprisingforming an aqueous solution comprising fibrinogen, fibrin-forming enzyme, and a fibrin hydrogel forming salt; wherein the fibrin hydrogel forming salt has a concentration greater than or equal to the threshold concentration to form a fibrin hydrogel;
reducing the salt concentration below the threshold concentration to form a fibrin hydrogel.
US Pat. No. 10,138,509

METHOD FOR GENERATING A THREE-DIMENSIONAL NUCLEIC ACID CONTAINING MATRIX

President and Fellows of ...

1. A method of identifying nucleic acids within a cell, comprising:contacting a plurality of nucleic acids having a relative three-dimensional spatial relationship within the cell with a matrix-forming material in a manner to substantially retain the relative three-dimensional spatial relationship;
using the matrix-forming material to form a three-dimensional polymerized matrix including the nucleic acids of the plurality of nucleic acids covalently bound to the three-dimensional polymerized matrix; and
detecting signals from the nucleic acids or derivatives thereof, thereby identifying the nucleic acids.
US Pat. No. 10,138,510

DUAL LABELING METHODS FOR MEASURING CELLULAR PROLIFERATION

LIFE TECHNOLOGIES CORPORA...

1. A method for measuring a change in cellular DNA synthesis:a) incubating a sample with an effective amount of a first nucleoside or nucleotide analog comprising an ethynyl group to form a primary incubated sample,
wherein the first nucleoside or nucleotide analog is ethynyl-deoxyuracil (EdU);
b) incubating the primary incubated sample with a second nucleoside or nucleotide analog comprising a halogen moiety to form a secondary incubated sample,
wherein the second nucleoside or nucleotide analog is BrdU, and wherein the first nucleoside or nucleotide analog is not incorporated into a DNA polymer when the second nucleoside or nucleotide analog is present;
c) incubating the secondary incubated sample with a first labeling reagent comprising an azide group that can undergo a [3+2] cycloaddition reaction with the ethynyl group of the first nucleoside or nucleotide analog and a second labeling reagent that is an antibody that binds to the second nucleoside or nucleotide analog to form a labeled sample; and
d) detecting the labeled sample wherein a level of incorporation of the first nucleoside or nucleotide analog is measured and allows establishment of a baseline rate of the cellular DNA synthesis and a level of incorporation of the second nucleoside or nucleotide analog is measured,
wherein a difference between the level of incorporation of the second nucleoside or nucleotide analog relative to the baseline rate indicates a change in cellular DNA synthesis,
with the proviso that there is no wash step prior to adding the second nucleoside or nucleotide analog.
US Pat. No. 10,139,022

HEATABLE PIPE

Evonik Degussa GmbH, Ess...

1. A heatable pipe, comprising:a layer (layer I) of a moulding compound comprising a east 40 wt. % of the following components:
1) 60 to 99 parts by wt. of a partly aromatic copolyamide containing monomer units obtained from
?) 30 to 90 mol % of a combination of hexamethylenediamine and terephthalic acid, and
?) 70 to 10 mol % of a combination of hexamethylenediamine and a linear aliphatic dicarboxylic acid having 8 to 19 carbon atoms;
wherein the mol % values relate to the sum of ?) and ?) and
wherein not more than 20% of the hexamethylenediamine is optionally replaced by the equivalent amount of another diamine and/or
wherein not more than 20% of the terephthalic acid is optionally replaced by the equivalent amount of another aromatic dicarboxylic acid and/or 1,4-cyclohexanedicarboxylic acid and/or
wherein not more than 20% of the repeating units containing hexamethylenediamine and linear aliphatic dicarboxylic acid are optionally replaced by the equivalent amount of units obtained from a lactam/an ?-aminocarboxylic acid having 6 to 12 carbon atoms,
2) 40 to 1 parts by wt. of an olefinic copolymer as impact modifier,
wherein the parts by wt. of 1) and 2) sum to 100; and
a conductor for electrical current which is embedded between an electrically insulating outer layer and an electrically insulating inner layer.
US Pat. No. 10,137,236

SELF-REGULATING DEVICE FOR MODULATING INFLAMMATION

1. A method of inhibiting tumor necrosis factor-alpha (TNF-?) comprising, providing blood of a patient to an extracorporeal bioreactor, wherein the extracorporeal bioreactor comprises: a compartment comprising cells and a selectively permeable membrane in contact with the cells that does not permit passage of the cells and which permits passage of TNF-? in the blood of the patient, wherein the cells comprise a chimeric gene comprising a response element operably linked to a sequence encoding a soluble TNF-? receptor (sTNFR), in which the response element causes expression of the sTNFR when the cells are contacted with the TNF-? in the blood of the patient; contacting the blood with the selectively permeable membrane, such that the TNF-? in the blood passes through the selectively permeable membrane and sTNFR produced by the cells passes into the blood; and returning the blood to the patient, thereby inhibiting TNF-?.
US Pat. No. 10,138,520

DIAGNOSTIC MIRNA MARKERS FOR ALZHEIMER

SIEMENS AKTIENGESELLSCHAF...

1. A method of treating Alzheimer's Disease in a patient in need thereof, said method comprisingadministering an anti-Alzheimer's Disease therapy to the patient, wherein a blood sample from the patient exhibits an expression level value of at least one miRNA selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 7, SEQ ID NO 56, SEQ ID NO 58, SEQ ID NO 59, SEQ ID NO 64, SEQ ID NO 65, SEQ ID NO 66, SEQ ID NO 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 73, SEQ ID NO 78, SEQ ID NO 85, SEQ ID NO 142 and SEQ ID NO 236 compared to a reference expression level value.
US Pat. No. 10,138,264

RECOMBINED MOLECULES AND PREPARATION THEREOF

VALENT TECHNOLOGIES LLC, ...

1. A method for preparation of a recombined molecule from vancomycin comprising the steps of:(a) cleavage of vancomycin with a protease;
(b) splitting the cleaved vancomycin molecules into two separate pools: a first pool and a second pool;
(c) acylating the cleaved vancomycin molecules of the first pool with an acylating agent to acylate all alcohols and amino groups of the cleaved vancomycin molecules of the first pool;
(d) methylating the cleaved vancomycin molecules of the second pool with a methylating agent to methylate all carboxylic acid moieties of the cleaved vancomycin molecules of the second pool;
(e) recombining the acylated cleaved vancomycin molecules of the first pool and the methylated cleaved vancomycin molecules of the second pool by forming peptide bonds with a peptide bond forming agent to afford a recombined molecule from vancomycin comprising acetyl protecting groups and methyl protecting groups; and
(f) removing all acetyl protecting groups and all methyl protecting groups present in the recombined molecule from vancomycin in step (e) by base hydrolysis to produce a recombined molecule from vancomycin.
US Pat. No. 10,138,523

CANCER BIOMARKER AND DIAGNOSTIC

1. A method for monitoring colorectal cancer in a subject, wherein the method comprises:(i) measuring the level of ATP11B and S100A11 gene expression or the quantity of protein or peptides resulting from ATP11B and S100A11 gene translation in samples from the subject from two or more successive time points;
(ii) comparing the level or quantity of both markers between the samples as measured in (i);
(iii) finding a deviation of at least about 40% (about 1.4-fold or more)_or no deviation of the quantity of both markers between the samples as compared in (ii); and
(iv) attributing the finding of deviation or no deviation to a change in the colorectal cancer in the subject between the two or more successive time points.
US Pat. No. 10,141,607

NONAQUEOUS ELECTROLYTE SECONDARY BATTERY

GS Yuasa International Lt...

1. A nonaqueous electrolyte secondary battery comprising a nonaqueous electrolyte,wherein the nonaqueous electrolyte contains 2-fluorotoluene and lithium difluorophosphate,
the content of the 2-fluorotoluene is 4 mass % or more and 8 mass % or less per the nonaqueous electrolyte, and
the content of the lithium difluorophosphate is 1 mass % or more and 6 mass % or less per the nonaqueous electrolyte.
US Pat. No. 10,138,533

METHOD FOR PRODUCING HIGH-PURITY CALCIUM

1. High-purity calcium having a purity, excluding gas components, Sr, and Ba, of 4N5 or higher and containing silicon as an impurity in an amount of: less than 0.05 ppm, produced by a process comprising the steps of:charging calcium starting material having a purity, excluding the gas components, of 4N or less into a crucible of a sublimation vessel;
performing first sublimation purification by heating at 750° C. to 800° C. so that calcium is sublimated and deposits (evaporates) onto the inner side wall of the sublimation vessel;
recovering the calcium purified by the first sublimation purification;
charging the calcium into a crucible of a sublimation vessel again;
performing second sublimation purification by heating at 750° C. to 800° C. so that the calcium is sublimated and deposits (evaporates) onto the inner side wall of the sublimation vessel; and
recovering the calcium having a purity, excluding gas components, Sr, and Ba, of 4N5 or higher and containing silicon as an impurity in an amount of less than 0.05 ppm.
US Pat. No. 10,138,534

NICKEL ALLOY

ROLLS-ROYCE plc, London ...

1. A nickel alloy having the following composition (in atomic percent unless otherwise stated): between 5.75 and 6.75 Al, between 4.5 and 5.8 Ti, between 0.5 and 1.3 Ta, up to 1% Nb, between 13.5% and 16% Cr, between 22and 27% Co, between 0.1 and 0.3% C, between 0.05 and 0.2% B, between 0.02 and 0.07% Zr, up to 1.1% W, between 1.4 and 2.85% Mo, up to 1% Fe, up to 0.7% Mn, up to 1% Si, up to 0.15% Hf, and up to 0.05% Mg; the balance being Ni and incidental impurities.
US Pat. No. 10,138,293

BIVALENT, BISPECIFIC ANTIBODIES

HOFFMANN-LA ROCHE, INC., ...

1. A bivalent, bispecific antibody comprising two pairs of light chains and heavy chains, each light chain comprising a variable region and a constant region, each heavy chain comprising a variable region and a constant region, wherein:a) the light chain and heavy chain of the first of the two pairs specifically bind to a first antigen, wherein the light chain comprises the following domains in N-terminal to C-terminal direction VL, CL and the heavy chain comprises the following domains in N-terminal to C-terminal direction VH, CH1, CH2, CH3; and
b) the light chain and heavy chain of the second of the two pairs specifically bind to a second antigen, wherein the light chain comprises the following domains in N-terminal to C-terminal direction VH, CL and the heavy chain comprises the following domains in N-terminal to C-terminal direction VL, CH1, CH2, CH3.
US Pat. No. 10,138,038

ANTIMICROBIAL DETECTABLE CABLE TIE

1. A cable tie comprising:a body having a composition wherein the composition comprises a base plastic, an antimicrobial additive, and a detectable additive selected from a detectable metal additive, an X-ray detectable additive and combinations thereof, and wherein the antimicrobial additive includes silver ion complex and at least one selected from the group consisting of copper ion complex, polychloro phenoxy phenol derivative, quaternary ammonium compound, and zinc pyrithione derivative, and
a head having a barb comprising an antimicrobial metallic barb material,
wherein the body and the head are integrally connected, and wherein the antimicrobial metallic barb material comprises a copper alloy selected from the group consisting of C28000, C11000, C51000, C70600, C26000, and C75200.
US Pat. No. 10,138,299

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

Bristol-Myers Squibb Comp...

1. A method of treating a tumor in a human subject in need thereof, comprising administering to the subject about 10 mg/kg of an anti-PD-L1 antibody every 2 weeks, wherein the anti-PD-L1 antibody is administered intravenously over 60 minutes infusion;wherein the tumor is derived from a bladder cancer of; and wherein the tumor is refractory to a platinum based chemotherapy.
US Pat. No. 10,138,301

MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2

GALAXY BIOTECH, LLC, Cup...

1. An isolated monoclonal antibody (mAb) that binds human fibroblast growth factor receptor 2 isoform IIIb (FGFR2 IIIb) comprising a light chain variable region comprising CDR1, CDR2, and CDR3 respectively defined by residues 24-34, 50-56, and 89-97 of SEQ ID NO. 1 and comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 respectively defined by residues 31-35, 50-66 and 99-103 of SEQ ID NO:4.
US Pat. No. 10,138,558

PRETREATMENT AGENT FOR ELECTROLESS PLATING, AND PRETREATMENT AND PRODUCTION OF PRINTED WIRING BOARD USING SAME

1. A pretreatment agent for electroless plating, comprising:a silane coupling agent;
a surfactant; and
ethylene-based glycol butyl ethers of formula: C4H9—(OC2H4)nOH where n is an integer of 1 to 4, and/or propylene-based glycol butyl ethers of formula: C4H9—(OC3H6)nOH where n is an integer of 1 to 4.
US Pat. No. 10,138,560

METHODS AND SYSTEMS UTILIZING A BORON-CONTAINING CORROSION INHIBITOR FOR PROTECTION OF TITANIUM SURFACES

Halliburton Energy Servic...

1. A method comprising:contacting a metal surface consisting of titanium or a titanium alloy with a corrosion inhibitor composition comprising a boron-containing compound, wherein the boron-containing compound comprises a boron-alkanolamine complex;
interacting the metal surface with a fluid phase comprising hydrofluoric acid or acidic fluoride ions; and
suppressing corrosion of the metal surface by the hydrofluoric acid or acidic fluoride ions with the boron-containing compound.
US Pat. No. 10,138,304

METHODS FOR INCREASING THE EXTRACTABLE RUBBER CONTENT OF NON-HEVEA PLANT MATTER

Bridgestone Corporation, ...

1. A method for increasing the extractable rubber content of non-Hevea plant matter without unduly increasing the extractable resin content comprising:utilizing a quantity of chopped non-Hevea plant matter having an average length of ½? to 4? and a maximum moisture content of 15 weight % and subjecting the chopped non-Hevea plant matter to at least one of
hammer milling utilizing a screen size of less than ½? and greater than or equal to 3/16?; and
roller milling with corrugated rolls having no more than 8 corrugations per inch,
thereby producing a quantity of milled non-Hevea plant matter having a maximum moisture content of 15 weight %, an extractable rubber content at least 30% higher than the pre-milled chopped non-Hevea plant matter and an extractable resin content of no more than 3 times the extractable rubber content.
US Pat. No. 10,138,308

CATALYST COMPONENT FOR THE PREPARATION OF NUCLEATED POLYOLEFINS

BOREALIS AG, (AT)

1. A process of obtaining a catalyst composition containing a catalyst component, the process comprising:a1) providing a solution of at least a Group 2 metal alkoxy compound (Ax) being the reaction product of a Group 2 metal compound (MC) and a monohydric alcohol (A) comprising in addition to the hydroxyl moiety at least one ether moiety optionally in an organic liquid reaction medium; or
a2) providing a solution of at least a Group 2 metal alkoxy compound (Ax?) being the reaction product of a Group 2 metal compound (MC) and an alcohol mixture of the monohydric alcohol (A) and a monohydric alcohol (B) of formula ROH, optionally in an organic liquid reaction medium; or
a3) providing a solution of a mixture of the Group 2 metal alkoxy compound (Ax) and a Group 2 metal alkoxy compound (Bx) being the reaction product of a Group 2 metal compound (MC) and the monohydric alcohol (B), optionally in an organic liquid reaction medium; or
a4) providing a solution of Group 2 metal alkoxy compound of formula M(OR1)n(OR2)mX2-n-m or mixture of Group 2 alkoxides M(OR1)n?X2-n? and M(OR2)m?X2-m?, where M is Group 2 metal, X is halogen, R1 and R2 are different alkyl groups of C2 to C16 carbon atoms, and 0 b) adding said solution from step a) to at least one compound (TC) of a transition metal of Group 4 to 6, and
c) obtaining the solid catalyst component particles,
d) washing said solidified particles,
e) recovering the solidified particles of the olefin polymerisation catalyst component, wherein an electron donor is added at any step prior to step c) and is a non-phthalic internal electron donor, and
wherein the catalyst component is further modified by a polymeric nucleating agent comprising vinyl compound units;
wherein the catalyst component is washed in step d) at least three times with at least one toluene and at least one TiCl4 washing step and 1 to 3 further washing steps with an aromatic and/or aliphatic hydrocarbon selected from toluene, heptane or pentane; and
wherein internal donor is added to either the toluene wash step and/or to the TiCl4 wash step, whereby the amount of donor added to the washing steps is in the range of 10 to 60 wt % of the total amount of donor used in catalyst preparation steps a) to d).
US Pat. No. 10,138,569

WELD CLEANING FLUID

Ensitech IP PTY LLP, Emu...

1. A stainless steel cleaning composition, comprising:an aqueous solution having a pH that is approximately neutral, said aqueous solution having from more than 30% to 60% by weight of a phosphoric acid salt, and having up to 20% by weight of a salt of a polyaminocarboxylic acid as a sequestering or chelating agent,
wherein said acid salt is selected to induce passivation of stainless steel through oxidation of chromium atoms within the stainless steel, and
all optional components of said composition are selected to be chemically unreactive with, and non-chemically-bonding to, metals.
US Pat. No. 10,138,314

RUBBER GRAFT COPOLYMER, AND THERMOPLASTIC RESIN COMPOSITION CONTAINING RUBBER GRAFT COPOLYMER

KANEKA CORPORATION, Osak...

1. A rubber graft copolymer comprising a core layer containing a rubber polymer and a shell layer grafted on the core layer satisfying all of the following (1) to (7):(1) the rubber graft copolymer polymerized under the presence of an alkaline metal salt of a phosphate compound,
(2) the rubber graft copolymer obtained by contacting a solution containing an alkaline earth metal chloride to a latex containing the rubber graft copolymer obtained by the emulsion polymerization to coagulate the copolymer,
(3) the rubber graft copolymer in which the phosphate compound remains as an alkaline earth metal salt in the rubber graft copolymer, the remaining amount of the alkaline earth metal salt of the phosphate compound is 400 ppm or more and 3000 ppm or less as an alkaline earth metal on a mass basis,
(4) the rubber graft copolymer obtained by polymerizing at conditions of pH of 5.0 to 9.0,
(5) the rubber graft copolymer in which the rubber polymer is a polybutadiene or a poly (butadiene-styrene),
(6) a concentration of monomers used in the polymerization of the shell layer is (i) 60 to 80% by mass of methyl methacrylate and 20 to 40% by mass of styrene, or (ii) 70 to 99% by mass of methyl methacrylate and 1 to 30% by mass of butylacrylate, or (iii) 30 to 40% by mass of glycidyl methacrylate, 45 to 55% by mass of methylmethacrylate, and 5 to 25% by mass of styrene, per 100% by mass of monomers constituting the shell layer, and
(7) the alkaline metal salt of the phosphate compound is polyoxyalkylene alkyl phenyl ether phosphate salt or polyoxyalkylene alkyl ether phosphate salt.
US Pat. No. 10,138,576

BIOCOMPATIBLE HYDROPHILIC COMPOSITIONS

3M INNOVATIVE PROPERTIES ...

1. A nonwoven web of fibers, wherein the fibers comprise a blend comprising:at least one thermoplastic aliphatic polyester;
an alkyl, alkenyl, aralkyl, or alkaryl anionic surfactant incorporated in the polyester; wherein the surfactant is selected from the group consisting of alkyl sulfate, alkenyl sulfate, alkaryl sulfate, aralkyl sulfate, alkylalkoxylated sulfate, alkyl sulfonate, alkenyl sulfonate, alkaryl sulfonate, aralkyl sulfonate, alkylalkoxylated sulfonate, alkyl phosphonate, alkenyl phosphonate, alkaryl phosphonate, aralkyl phosphonate, alkyl phosphate, alkenyl phosphate, alkaryl phosphate, aralkyl phosphate, alkyl alkoxylated phosphate, di(C8-C18) sulfosuccinate salts, C8-C22 alkyl sarcosinate salts, C8-C22 alkyl lactylate salts, and combinations thereof; wherein the surfactant is present in a concentration sufficient to make the nonwoven web durably hydrophilic and absorbent and instantaneously wettable; and
a surfactant carrier;
wherein the fibers are 20 micrometers or less in diameter;
wherein the surfactant is soluble in the carrier at greater than 10% by weight such that the surfactant and carrier form a visually transparent solution in a 1-cm path length glass vial when heated to 150° C.
US Pat. No. 10,138,577

POLYPHENYLENE SULFIDE FIBERS, AND MANUFACTURING METHOD THEREFOR

Toray Industries, Inc., ...

1. A poly(phenylene sulfide) fiber containing 1-10% by weight of a poly(phenylene sulfide) oligomer having a weight-average molecular weight of 5,000 or less, having a difference between a cold crystallization heat quantity (?Hc) and a crystal melting heat quantity (?Hm) during temperature rising in DSC, ?Hm??Hc, of 25 J/g or larger, and having an elongation of less than 40% and a strength of 3.0 cN/dtex or higher.
US Pat. No. 10,138,321

PROCESS FOR PRODUCTION OF OXYMETHYLENE COPOLYMER

MITSUBISHI GAS CHEMICAL C...

1. A method for producing an oxymethylene copolymer, comprising a polymerization step for cationically polymerizing trioxane and a comonomer at a polymerization temperature of from 135 to 300° C. in the presence of at least one salt of a protonic acid having a molecular weight of 1,000 or less, and at least one polymerization initiator selected from the group consisting of protonic acids having a molecular weight of 1,000 or less, protonic acid anhydrides having a molecular weight of 1,000 or less, and protonic acid ester compounds having a molecular weight of 1,000 or less, wherein the trioxane and comonomer used in the polymerization step contain metal components in a total concentration of 300 ppb by mass or less.
US Pat. No. 10,138,326

METHOD OF PRODUCING COPOLYESTER MATERIAL WITH PEPTIDE AND COPOLYESTER MATERIAL WITH PEPTIDE THEREOF

Camangi Corporation, Tai...

1. A method of producing copolyester material with peptide, comprising:putting ethylene glycol (EG), collagen peptide, and benzenedicarboxylic acid into a container, and mixing the ethylene glycol, the collagen peptide, and the benzenedicarboxylic acid to form a mixture, wherein in the mixture, a molar ratio of the collagen peptide, the ethylene glycol, and the benzenedicarboxylic acid is (0.47-0.60): (0.90-1.10): (1.14-1.26); heating the mixture for executing an esterification reaction, to produce esters and water;
heating the esters to a first temperature, and stirring the esters via a mixer;
in a specific period, decreasing a pressure in the container to a first pressure for executing a polycondensation reaction; and
decreasing the pressure in the container to a second pressure, and stirring the esters via the mixer, to produce a copolyester material with peptide.
US Pat. No. 10,138,328

METHOD FOR PRODUCING POLYETHER CARBONATE POLYOLS

Covestro Deutschland AG, ...

1. A process for preparing polyether carbonate polyols, comprising reacting alkylene oxide with carbon dioxide in the presence of an H-functional starter compound and double metal cyanide catalyst, wherein the process comprises:(?) optionally, pretreating a double metal cyanide catalyst (DMC catalyst) at a temperature of 50 to 200° C. and/or reduced pressure (absolute) of 10 mbar to 800 mbar in a first reactor,
(?) contacting the double metal cyanide catalyst and suspension medium with alkylene oxide to obtain a first reaction mixture in a first reactor;
and
(?) continuously adding the first reaction mixture, alkylene oxide, carbon dioxide and optionally H-functional starter compound to a second reactor,
wherein at least one H-functional starter compound is added at least in one of steps (?) and (?) and
wherein reaction products formed in step (?) are withdrawn continuously from the second reactor.
US Pat. No. 10,138,330

SILICONE ELASTOMERS CAPABLE OF LARGE ISOTROPIC DIMENSIONAL CHANGE

Lawrence Livermore Nation...

1. A method for making a microfluidic device, comprising forming a microfluidic pattern comprising at least one line having a width of 500 ?m or less with a silicone-based elastomer, wherein the silicone-based elastomer comprises a network of crosslinked polysiloxane having its internal space occupied by a guest molecule, and removing the guest molecule from the silicone-based elastomer to isotropically reduced the volume of the silicone-based elastomer by at least 20%.
US Pat. No. 10,138,593

SIZING AGENT-COATED CARBON FIBERS, PROCESS FOR PRODUCING SIZING AGENT-COATED CARBON FIBERS, PREPREG, AND CARBON FIBER REINFORCED COMPOSITE MATERIAL

Toray Industries, Inc., ...

1. Sizing agent-coated carbon fibers comprising:a sizing agent coating that includes:
an aliphatic epoxy compound (A) that has three or more epoxy groups and at least one hydroxy group in a molecule,
an aromatic epoxy compound (B1) as a type of aromatic compound (B), and
an aromatic ester compound (C1); and
carbon fibers coated with the sizing agent,whereinthe sizing agent contains the aliphatic epoxy compound (A) in an amount of 35 to 65% by mass relative to the total amount of the sizing agent exclusive of solvent;
the sizing agent contains the aliphatic epoxy compound (A) and the aromatic epoxy compound (B1) in a mass ratio (A)/(B1) of 52/48 to 80/20;
the sizing agent contains the aromatic ester compound (C1) in an amount of 2 to 35% by mass relative to the total amount of the sizing agent exclusive of solvent;
each of the aliphatic epoxy compound (A) and the aromatic epoxy compound (B1) has a surface tension of 35 to 45 mJ/m2 at 125° C.;
the sizing agent-coated carbon fibers have an (a)/(b) ratio of 0.50 to 0.90, wherein (a) is a height (cps) of a component at a binding energy (284.6 eV) assigned to CHx, C—C, and C?C and (b) is a height (cps) of a component at a binding energy (286.1 eV) assigned to C—C in a C1s core spectrum of a surface of the sizing agent applied onto the carbon fibers analyzed by X-ray photoelectron spectroscopy using AlK?1,2 as an X-ray source at a photoelectron takeoff angle of 15°; and
the carbon fibers have a surface carboxy group concentration COOH/C of 0.003 to 0.015 and a surface hydroxy group concentration COH/C of 0.001 to 0.050 determined by chemical modification X-ray photoelectron spectroscopy.
US Pat. No. 10,137,168

VETERINARY DECORIN COMPOSITIONS AND USE THEREOF

CATALENT PHARMA SOLUTIONS...

1. A veterinary decorin core protein molecule that is at least 98% identical to one of SEQ ID NOs:4, 7, 10, 13, 16, 19, 22, and 27, wherein the veterinary core protein molecule comprises an aspartic acid residue at the N-terminus and does not comprise a serine residue at the fourth amino acid from the N-terminus.
US Pat. No. 10,137,169

COMPOSITIONS AND USES THEREOF

Follicum AB, Lund (SE)

1. A composition for stimulating hair growth in a mammal comprising:(a) a modified osteopontin polypeptide in which an RGD domain is inactivated; and
(b) a pharmaceutically acceptable and/or cosmetically acceptable excipient, carrier or diluent,wherein the modified polypeptide comprises the amino acid sequence of SEQ ID NO: 63.
US Pat. No. 10,137,171

METHODS OF TREATMENT USING A PENTAPEPTIDE DERIVED FROM THE C-TERMINUS OF GLUCAGON-LIKE PEPTIDE 1 (GLP-1)

The General Hospital Corp...

wherein Xaa can be Gly, Gly-Arg, Gly-Arg-Gly, or absent,and a physiologically acceptable carrier, to a subject in need thereof.
US Pat. No. 10,137,172

ADMINISTRATION REGIME

1. An insulin titration method comprising:(a) obtaining a fasting blood or plasma sample, or non-invasive glucose measurement from an individual in need of treatment of type 2 diabetes;
(b) performing a single fasting blood or plasma glucose measurement on the sample obtained in (a);
(c) using the single fasting blood or plasma glucose measurement obtained in (b) to determine a LysB29(N?-hexadecandioyl-?-Glu) des(B30) human insulin (insulin degludec) dose to be administered; and
(d) administering said insulin to the individual at the dose determined in step (c);wherein subsequent doses of insulin are titrated by repeating step (a) and (b), the measurement being:?3.9 mmol/L (?70 mg/dL): the dose administered in step (d) is reduced by 4 U compared to the dose previously administered; or
4 to 5 mmol/L (71 to 90 mg/dL): the dose administered in step (d) is unaltered compared to the dose previously administered; or
?5.1 mmol/L (?91 mg/dL): the dose administered in step (d) is increased by 4 U compared to the dose previously administered;wherein step (d) is performed for an administration period of at least 3 days between two consecutive titrations; andwherein comparable improvements in HbA1c levels are seen relative to titration methods that are based on an average of at least three consecutive fasting blood glucose measurements per week.
US Pat. No. 10,138,196

PROCESS FOR PREPARING AN UNSATURATED CARBOXYLIC ACID SALT

BASF SE, Ludwigshafen (D...

1. A catalytic process for preparing an ?, ?-ethylenically unsaturated carboxylic acid salt, the process comprising:a) contacting an alkene and carbon dioxide with a carboxylation catalyst and an alkoxide, the alkoxide having a secondary or tertiary carbon atom directly bound to a [O?] group, to obtain a crude reaction product comprising the ?,?-ethylenically unsaturated carboxylic acid salt and an alcohol byproduct which is a conjugate acid of the alkoxide,
b) contacting at least part of the crude reaction product with a polar solvent such that a first liquid phase in which the ?,?-ethylenically unsaturated carboxylic acid salt is enriched, and a second liquid phase in which the carboxylation catalyst is enriched, are obtained, and
c) distilling an alcohol byproduct off from the first liquid phase.
US Pat. No. 10,137,173

ANTIVIRAL ACTIVITY OF GAS6 INHIBITOR

Aravive Biologics, Inc., ...

1. A method of inhibiting entry of an enveloped virus that expresses or incorporates phosphatidylserine in its outer membrane, into a cell, the method comprising:administering a soluble AXL variant polypeptide in a dose effective to inhibit the interaction between phosphatidylserine present at the outer membrane of the virus and of GAS6, wherein the virus is a filovirus, a lentivirus, a poxvirus, or a herpesvirus; and wherein said soluble AXL variant polypeptide lacks the AXL transmembrane domain and comprises amino acid modifications selected from the group consisting of:
(i) Gly32Ser, Asp87Gly, Val92Ala, and Gly127Arg; and
(ii) Gly32Ser, Ala72Val, Asp87Gly, Val92Ala, and Gly127Arg.
US Pat. No. 10,138,197

DIRECT CATALYTIC PARTIAL OXIDATION OF ALLYL ETHER

EXXONMOBIL RESEARCH AND E...

1. A process for forming allyl acrylate, comprising contacting allyl ether with a solvent, wherein the solvent is selected from acetonitrile, chloroform, dichloromethane, N,N-dimethylformamide, N,N-dimethyl acetamide, dimethyl sulfoxide, or dimethylcarbonate, and with an oxidant, wherein the oxidant is selected from oxygen, oxygen-containing gases, peroxides, and mixtures thereof in the presence of a mesoporous manganese oxide (MnOx) catalyst.
US Pat. No. 10,137,174

METHODS AND MATERIALS FOR TREATING CANCERS THAT EXPRESS REDUCED LEVELS OF WILD-TYPE P53 POLYPEPTIDES

Mayo Foundation for Medic...

1. A method for treating cancer in a mammal, wherein said method comprises:(a) identifying a mammal as having cancer cells that express a reduced level of wild-type p53 polypeptides, and
(b) administering, to said mammal, a USP10 polypeptide or composition that increases USP10 polypeptide expression or activity within said cancer cells and increases wild-type p53 polypeptide expression with said cancer cells, thereby reducing cancer cell proliferation within said mammal.
US Pat. No. 10,138,199

HIGH ASPECT RATIO LAYERED DOUBLE HYDROXIDE MATERIALS AND METHODS FOR PREPARATION THEREOF

Saudi Arabian Oil Company...

1. A method for preparing adamantane-intercalated layered double-hydroxide (LDH) particles, the method comprising:adding to an aqueous solution a first precursor and a second precursor to form an initial mixture, where:
the first precursor is Al(OH)3 or Al2O3;
the second precursor is a hydroxide M(OH)2 or an oxide MO, where M is a metal of oxidation state +2; and
the initial mixture has a M/AI molar ratio from 1 to 5;
the initial mixture has a solid loading of less than 10 weight % solids, based on a total weight of the initial mixture;
adding to the initial mixture an amount of adamantane to form a reaction mixture having an Al/adamantane molar ratio from 0.5 to 2; and
heating the reaction mixture to produce the adamantane-intercalated LDH particles, where the adamantane-intercalated LDH particles have an aspect ratio greater than 100, the aspect ratio defined by a width of an adamantane-intercalated LDH particle divided by a thickness of the adamantane-intercalated LDH particle.
US Pat. No. 10,136,666

DEEP EUTECTIC SOLVENTS AND FLAVOUR GENERATION

Nestec S.A., Vevey (CH)

1. A process for the preparation of a flavor composition comprising the steps:forming a deep eutectic solvent;
preparing a reaction mixture comprising the deep eutectic solvent and flavor precursors selected from the group consisting of amino acids and peptides; and heating the reaction mixture to form aroma compounds, wherein the deep eutectic solvent is a liquid comprising a combination of at least two compounds solid at 25° C. and comprises water and/or glycerol in an amount insufficient to dissolve all the compounds solid at 25° C. individually, or in an amount such that all the compounds solid at 25° C. are simultaneously saturated at 25° C., wherein the flavor precursors comprise the compounds solid at 25° C., and wherein the at least two compounds solid at 25° C. are selected from the group consisting of: amino acids; organic acids having 6 carbons or fewer; monosaccharides or disaccharides; sugar alcohols having 12 carbons or fewer; choline chloride; betaine; carnitine; edible salts of sodium, potassium, magnesium or calcium; ribonucleotides; and urea; with the proviso that the two compounds are not both edible salts of sodium, potassium, magnesium or calcium; or are not both ribonucleotides.
US Pat. No. 10,137,178

DENTAL GEL COMPOSITION OF PAPAIN FOR THE ATRAUMATIC TREATMENT OF CARIES AND METHOD OF PREPARING SAME

BRIX USA, LLC, Newark, D...

1. A dental composition of papain in the form of a gel for the atraumatic treatment of caries comprising papain with a final activity of at least 3,000 U/mg, wherein the papain is bio-encapsulated in a mixture comprising all of the following ingredients:pH=7 buffer,
a C3-6 polyol,
pectin,
C2-6 alkanolamine,
a nonionic emulsifier,
optionally a pharmaceutically acceptable coloring agent
a preservative, and
a solvent,
wherein the composition does not include chloramine.
US Pat. No. 10,138,460

DEVICES, SYSTEMS AND METHODS FOR THE PRODUCTION OF HUMANIZED GUT COMMENSAL MICROBIOTA

1. A method for ex vivo production of human gut microbiota, comprising:screening a first sample of gut microbiota obtained from a first human subject to detect or remove ova, parasites, or viruses;
immobilizing the screened gut microbiota on a growth template coated with human cells, tissue extracts, adhesive proteins, or commensal colonizing factors;
seeding a synthetic, ex vivo culture medium with the immobilized sample;
adding nutrients to the synthetic culture medium to produce both cultured aerobic and anaerobic gut microbiota;
maintaining the temperature and gas gradients of the culture medium so as to be similar to the human gut; and
harvesting the cultured gut microbiota.
US Pat. No. 10,139,744

ELECTROSTATIC LATENT IMAGE DEVELOPING TONER

KYOCERA Document Solution...

8. An electrostatic latent image developing toner comprising toner particles each including a toner core and a shell layer covering a surface of the toner core, whereinthe shell layer contains a hydrophilic thermosetting resin and a hydrophobic thermoplastic resin,
the hydrophilic thermosetting resin is a resin having at least one functional group selected from the group consisting of oxazoline groups, carbodiimide groups, and isocyanate groups,
the hydrophobic thermoplastic resin is exposed at surfaces of the toner particles, and
the hydrophilic thermosetting resin is a polymer of a monomer containing at least one compound selected from the group consisting of 2-isopropenyl-2-oxazoline, 2-(penta-4-ynyl)-2-oxazoline, 2-isocyanatoethyl acrylate, and 2-isocyanatoethyl methacrylate.
US Pat. No. 10,138,204

METHOD FOR PRODUCING N-RETINOYLCYSTEIC ACID ALKYL ESTER

ARDENIA INVESTMENTS, LTD,...

1. A method for producing derivatives of N-retinoylaminoalkane sulfonic acid, the method comprising providingi) a first solution comprising an aminoalkane sulfonic acid selected from the group consisting of cysteic acid and alkyl ester thereof, cysteinesulfinic acid and alkyl ester thereof, homocysteic acid and alkyl ester thereof, homocysteinesulfinic acid and alkyl esters thereof, taurine and derivatives thereof, an alcohol selected from aliphatic alcohols comprising 1 to 4 carbon atoms and a first base selected from trialkylamines,
ii) a second solution comprising a retinoic acid, a chloroformate, an aprotic solvent and a second base,
adding first and second solutions in any order to a reaction vessel thereby forming a reaction mixture comprising at least a liquid phase being one phase, mixing said reaction mixture, wherein retinoic acid, aminoalkane sulfonic acid and chloroformate are all soluble and present in said liquid phase and the derivatives of N-retinoylaminoalkane sulfonic acid are formed in said liquid phase under conditions characterised as being substantially free from oxidizing compounds.
US Pat. No. 10,137,437

METHOD FOR PRODUCING A CATALYST FOR THE PARTIAL OXIDATION/AMMOXIDATION OF OLEFINS

Clariant Corpoation, Lou...

1. A method for producing a catalyst which includes as the catalytically active component a compound having the general formula MoxBiyFezAaBbCcDdOv, where A stands for Ni and/or Co, B stands for one or more metals selected from Mg, Cr, Mn, Zn, Ce, and Ca and combinations thereof, C stands for W, and D stands for one or more alkali metals, where x stands for a number from 10 to 14, y stands for a number from 0.1 to 5, z stands for a number from 0.5 to 5, a stands for a number from 1 to 10, b stands for a number from 0.1 to 6, c stands for a number from ?0 to 2, d stands for a number from 0.02 to 2, and v is determined by the oxidation state of the elements, the method including the following steps:a) providing a solution in which all precursor compounds of the Mo, Bi, Fe, A, B, C and D components of the catalytically active component are essentially completely dissolved in a suitable solvent;
b) bringing the solution obtained in step a) into contact with a chemically inert, porous support having a specific surface of 1 to 500 m2/g; and
c) heat treatment of the material obtained in step b), in which the precursor compounds of the catalytically active component are converted to their oxides.
US Pat. No. 10,137,182

CANCER VACCINES AND VACCINATION METHODS

Immunocellular Therapeuti...

1. A composition comprising a pharmaceutically acceptable carrier, an adjuvant, and a mixture of at least one major histocompatibility complex (MHC) class I peptide epitope of 8-10 amino acids in length derived from a mesothelin antigen variant having an amino acid sequence selected from the group consisting of: SEQ ID NOs: 19-25 and at least one MHC class I peptide epitope of 8-10 amino acids in length derived from each of at least six different antigens or variants thereof selected from the group consisting of:a mesothelin antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 15-18;
an NY-ESO-1 antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NO: 26 and SEQ ID NO: 27;
an FBP antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NO: 28 and SEQ ID NO: 29;
a HER-2/neu antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 30-48;
an IL-13 receptor ?2 antigen, wherein the MHC class I peptide epitope has an amino acid sequence of SEQ ID NO: 49;
a MAGE-A1 antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 50-55;
an EphA2 antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 56-68;
a p53 antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:69-80;
a k-Ras antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:81-86;
an Ep-CAM antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:87-91;
a MUC1 antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NO:92 and SEQ ID NO:93;
a survivin antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:94-98;
an hTERT antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:99-104; and
a WT1 antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 105-109.
US Pat. No. 10,138,719

METHOD OF EXTRACTING BITUMEN FROM OIL SANDS WITH A PROPYLENE OXIDE CAPPED GLYCOL

Dow Global Technologies L...

1. A bitumen recovery process comprising a step of treating oil sands with a propylene oxide capped glycol ether, wherein:the oil sands are recovered by surface mining and transported to a treatment area for the step of treating the oil sands with the propylene oxide capped glycol ether or the oil sands are recovered by in situ production and in situ treatment occurs during the step of treating the oil sands with the propylene oxide capped glycol ether, and
the propylene oxide capped glycol ether is described by the following structure:
RO—(C2H4O)n—CH2CH(CH3)OHwherein R is a linear, branched, cyclic alkyl, phenyl, or alkyl phenyl group and n is 1 to 10.
US Pat. No. 10,137,439

PROCESS AND CATALYST FOR THE PRODUCTION OF PYRIDINE AND ALKYL DERIVATIVES THEREOF

1. A method of enhancing the catalytic activity of zinc containing zeolite-based heterogeneous catalyst for the production of pyridine and its alkyl derivatives during a base synthesis reaction, the method comprising:(1) preparing an aqueous slurry comprising components (a) a zeolite selected the group consisting of ZSM-5, ZSM-11 and combinations thereof, (b) optionally zinc, (c) a binder and (d) clay in amounts sufficient to provide an L/B ratio of about 1.5 to about 4.0 in the final catalyst composition;
(2) spray drying the slurry to provide catalyst particles having a particle size of about 40 ?m to about 200 ?m;
(3) calcining the particles to provide a final catalyst composition having an L/B ratio of about 1.5 to about 4.0.
US Pat. No. 10,137,184

SCAFFOLDS FOR CELL TRANSPLANTATION

President and Fellows of ...

1. A cancer vaccine device comprising a scaffold composition comprising a polymer matrix and having open, interconnected macropores;a granulocyte-macrophage colony stimulating factor (GM-CSF) that recruits immune cells selected from macrophages, T-cells, B-cells, NK cells, and dendritic cells;
a tumor antigen; and
an immune response-promoting bioactive factor comprising a small molecule, wherein the GM-CSF, the tumor antigen, or the immune response-promoting bioactive factor is incorporated into or coated onto said scaffold composition.
US Pat. No. 10,137,441

METHOD FOR PRODUCING ALUMINOSILICATE CATALYST, ALUMINOSILICATE CATALYST, AND METHOD FOR PRODUCING MONOCYCLIC AROMATIC HYDROCARBONS

1. A method for producing an aluminosilicate catalyst, comprising:a first phosphorus treatment step of treating a crystalline aluminosilicate with a first phosphorus compound, wherein the crystalline aluminosilicate comprises at least one component selected from the group consisting of medium pore zeolites and large pore zeolites as a main component,
mixing a phosphorus-treated crystalline aluminosilicate obtained in the first phosphorus treatment step with a binder, molding a mixture of the phosphorus-treated crystalline aluminosilicate and the binder to form a molded body, and then firing the molded body, and
a second phosphorus treatment step of treating the fired molded body with a second phosphorus compound.
US Pat. No. 10,138,209

PROCESS FOR PURIFYING AN IONIC LIQUID

Evonik Degussa GmbH, Ess...

1. A process for purifying an ionic liquid of the structure Q+A?, wherein Q+ is a 1,3-dialkylimidazolium ion, and wherein A? is selected from the group consisting of: dialkyl phosphate; alkyl sulphate; alkyl sulphonate; alkyl carboxylate; chloride; hydrogen sulphate; dihydrogen phosphate; monoalkyl hydrogen phosphate; and nitrate;wherein the ionic liquid of the structure Q+A? is subjected to a stripping with water vapour having a temperature of ?99° C.
US Pat. No. 10,138,466

COMPOSITIONS AND METHODS FOR DIFFERENTIATING STEM CELLS INTO CELL POPULATIONS COMPRISING BETA-LIKE CELLS

REGENERATIVE MEDICAL SOLU...

1. A kit, comprising:differentiation medium comprising a B27 serum-free medium, IGF I, IGF II, FGF7, insulin, nicotinamide, exendin-4, ALK5i II, and forskolin.
US Pat. No. 10,137,187

RECOMBINANT SUBUNIT DENGUE VIRUS VACCINE

1. A method for raising an immune response in a human patient, the method comprising administering a therapeutically effect amount of an immunogenic composition to the patient, wherein the immunogenic composition comprises an effective amount of purified dengue virus envelope (“E”) protein monomers of serotype DEN-1, DEN-2, DEN-3, and DEN-4, a pharmaceutically acceptable excipient, and an effective amount of adjuvant; wherein the E proteins each constitute approximately 80% of the length of wild type E starting from amino acid residue 1 at its N-terminus, such that said E protein is secretable into growth medium when expressed recombinantly in a host cell; wherein the amount of DEN4 E protein is about 1.5 to about 3 times the individual amounts of DEN1, DEN2, and DEN3 E proteins, and wherein the composition induces the production of neutralizing antibodies in human subjects.
US Pat. No. 10,138,468

METHOD FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO MULTI-COMPETENT RENAL PRECURSORS

Hoffmann-La Roche Inc., ...

1. A method for differentiating human or mouse pluripotent stem cells into renal precursor cells expressing SIX2, WT1 and SALL1, the method comprising the steps of:a) providing a monolayer of human or mouse pluripotent stem cells in a pluripotency medium,
b) incubating the cells of step a) in an adherent culture for at least three days in a medium supplemented with 3-(3-amino-phenyl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione and recombinant bone morphogenic protein-4 (BMP4), and
c) differentiating the cells of step b) in a serum-free medium supplemented with recombinant bone morphogenic protein-7 (BMP7) and retinoic acid, to produce renal precursor cells expressing SIX2, WT1 and SALL1.
US Pat. No. 10,138,471

INSERTION OF CHARGE IN THE HYDROPHOBIC INTERIOR OF PROTEINS AS A STRATEGY FOR ENGINEERING PH-SENSITIVE SWITCHES

THE JOHNS HOPKINS UNIVERS...

1. A non-naturally occurring protein comprising an artificial pH-sensitive conformational switch that responds to a change in pH, within a range of pH 5.0 to pH 9.0, by causing a cooperative unfolding transition of the protein, wherein the protein comprises two or more ionizable amino acid residues selected from Lys, Asp, and Glu, that titrate with a pKa value shifted relative to the normal pKa value in water for the one or more ionizable amino acid residues, and wherein the two or more ionizable amino acid residues comprise two or more alternative amino acid residues that have been substituted for two or more amino acid residues in an internal region of the protein.
US Pat. No. 10,138,473

THERMOSTABLE PROTEASE VARIANTS

1. A polypeptide having protease activity comprising at least 95% identity to amino acids 1 to 177 of SEQ ID NO: 2 and a substitution at position 79 using SEQ ID NO: 2 for numbering, wherein the polypeptide has improved thermostability compared to the protease shown in amino acids 1 to 177 of SEQ ID NO: 2.
US Pat. No. 10,138,476

USING RNA-GUIDED FOKI NUCLEASES (RFNS) TO INCREASE SPECIFICITY FOR RNA-GUIDED GENOME EDITING

The General Hospital Corp...

1. A composition comprising:a nucleic acid encoding an RNA-guided FokI Nuclease (RFN) fusion protein comprising a FokI catalytic domain sequence fused to the amino terminus of a catalytically inactive Streptococcus pyogenes CRISPR-associated 9 (dCas9) protein comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 5, wherein said catalytically inactive S. pyogenes Cas9 has point mutations at amino acid residues corresponding to positions (i) D10, E762, H983, or D986, and (ii) H840 or N863 of S. pyogenes Cas9, an intervening linker from 2 to 30 amino acids; and
a nucleic acid encoding two guide RNAs that direct said RFN fusion protein to a first target genomic sequence and a second target genomic sequence, wherein the guide RNAs that direct said RFN fusion protein to said first target genomic sequence and said second target genomic sequence are spaced 10 to 20 nucleotides apart, and said first target genomic sequence comprises a PAM recognition sequence positioned upstream of said first target genomic sequence and said second target genomic sequence comprises a PAM recognition sequence positioned downstream of said second target genomic sequence.
US Pat. No. 10,137,452

THERMAL UNIFORMITY FOR THERMAL CYCLER INSTRUMENTATION USING DYNAMIC CONTROL

LIFE TECHNOLOGIES CORPORA...

1. A method for performing polymerase chain reactions (PCR), the method comprising:measuring a first temperature, by a first sensor, of a first sample block sector of a sample block;
measuring a second temperature, by a second sensor, of a second sample block sector of the sample block, wherein the second sample block sector is located adjacent to the first sample block sector;
calculating, by a controller, a difference in temperature between the first temperature and the second temperature; and
adjusting, by the controller, the first temperature of the first sample block sector based on the difference in temperature to increase thermal uniformity across the first sample block sector and the second sample block sector during a PCR thermal protocol.